Abstract Antepartum depression and anxiety are risk factors for postpartum depression (PPD). Postpartum abnormalities in hypothalamic-pituitary-adrenal (HPA) reactivity are associated with PPD. It is not known if antepartum HPA abnormalities exist in women at risk for PPD (AR-PPD). We measured salivary cortisol response to the Trier Social Stress Test (TSST) in 44 (24 AR-PPD, 20 healthy comparison) pregnant women. Depression and anxiety were measured using the Edinburgh Postnatal Depression Scale (EPDS) and Spielberger StateTrait Anxiety Inventory-State (STAI-S). We analyzed longitudinal changes in cortisol using generalized estimating equation methods to control for the correlation within subjects at the six TSST time points. Group differences in area under the curve (AUC) were examined. A majority (70.8 %) of the AR-PPD had prior depression. EPDS total score was higher in AR-PPD vs. comparison women (mean EPDS = 9.8 ± 4.9 vs. mean EPDS = 2.4 ± 2.0 respectively, p < 0.001). Mean STAI-S total score was higher in AR-PPD vs. comparison women at all TSST time points and over time (z = 2.71, df = 1, p = 0.007). There was no significant difference in cortisol concentration over time between groups. We observed no detectable difference in cortisol response to psychosocial stress induced by the TSST despite clinically significant between-group differences in current/past depression and current symptomatology.
Introduction
Postpartum depression (PPD) affects one in eight women (Cox et al. 1993 ) and negatively impacts infant attachment, cognitive development, and behavior. The presence of antepartum anxiety or depressive symptoms during pregnancy increases the risk for the development of PPD (Beck 2001) and may represent an early manifestation of the disorder.
Recently, DSM-5 revised the Bpostpartum onset^specifier for major depression to Bperipartum onset^in recognition that 50 % of Bpostpartum^major depressive episodes begin antepartum (Diagnostic and Statistical Manual of Mental Disorders and DSM-5 (American Psychiatric Association 2013) . Abnormalities in the hypothalamic-pituitary-adrenal (HPA) axis during the peripartum period have been suggested as a possible vulnerability factor for developing peripartum depressive and anxiety disorders (O'Keane et al. 2011; Smith et al. 1990 ).
In healthy women, pregnancy is associated with physiological changes in the HPA axis including suppressed hypothalamic corticotropin-releasing hormone (CRH) and increased basal plasma CRH, adenocorticotropin (ACTH), and cortisol concentrations (Mastorakos and Ilias 2003; Nolten et al. 1980) . Some studies of maternal HPA response to pharmacological and physical stressors in healthy pregnant women suggest that there is a dampened response to these stressors across gestation (Buss et al. 2009; Entringer et al. 2010; Schulte et al. 1990 ); other studies suggest comparable antepartum HPA responsivity to stress to non-pregnant women (De Weerth et al. 2007; Giesbrecht et al. 2013; Nierop et al. 2006a) .
Preliminary studies which examined healthy euthymic pregnant women who developed postpartum depressive symptoms report abnormalities in antepartum HPA responsivity to pharmacologic and psychosocial stressors. Nierop et al. (2006a, b) reported higher cortisol reactivity to psychosocial stress induced by the Trier Social Stress Test (TSST) in healthy pregnant women who later developed mild depressive symptoms within 2 weeks of delivery (Nierop et al. 2006b) . In an experimental model of pregnancy, women with a history of PPD demonstrated a greater cortisol response to ovine CRH stimulation in the presence of elevated levels of gonadal steroids compared with healthy comparison subjects (Bloch et al. 2005) , suggesting that euthymic women with a history of PPD have an enhanced sensitivity of the HPA axis to gonadal steroids. However, it is not known if the antepartum salivary cortisol response to the TSST differs in women with a history of PPD or women with antepartum depressive and anxiety symptoms compared to healthy comparison women at low risk for developing PPD. Since up to a quarter of pregnant women have depressive or anxiety symptoms, it is important to determine if there are changes in salivary cortisol response in these women as it may represent a marker of those women who go on to develop PPD.
Given the above evidence of an abnormal antepartum cortisol response to the TSST in euthymic women who later developed postpartum depressive symptoms (Nierop et al. 2006b ), we examined basal and dynamic salivary cortisol response to the TSST (Kirschbaum et al. 1993a) in pregnant women at-risk for PPD (AR-PPD) compared to healthy comparison pregnant women. Our aim was to examine potential biological underpinnings of the aforementioned antepartum risk factors for PPD. Since antepartum depressive and anxiety symptoms may be an early manifestation of PPD (Diagnostic and Statistical Manual of Mental Disorders and DSM-5 (American Psychiatric Association 2013; Righetti-Veltema et al. 1998; Stowe and Nemeroff 1995) , we hypothesized that AR-PPD women would have exaggerated salivary cortisol stress reactivity as compared to the healthy comparison women.
Materials and methods

Participant selection
English-speaking pregnant subjects were consented and screened for eligibility with the Edinburgh Postnatal Depression Scale (EPDS) (Cox et al. 1987 ) at 24-34 weeks gestational age as determined by first trimester ultrasound. A total of 44 eligible women between 18 and 40 years old enrolled in the study. Two groups were enrolled: (1) 20 healthy low-risk healthy comparison women and (2) 24 AR-PPD women. The EPDS was used to assess peripartum depressive and anxiety symptoms (Cox et al. 1987; Lydsdottir et al. 2014) , and a cut-off score of 10 was chosen based on validation of the EPDS during pregnancy (Berrettini et al. 1982) . The healthy comparison group included women with an EPDS ≤5, and no current or past psychiatric diagnosis or family history of psychiatric illness, as ascertained by clinical and research interviews (First et al. 2001) conducted by a boardcertified psychiatrist. The AR-PPD group included women atrisk for developing PPD. As the EPDS is not sufficiently accurate in predicting risk of postpartum depressive symptoms alone (Meijer et al. 2014) , the AR-PPD group included women who had an elevated EPDS score (indicating current depressive and/or anxiety symptomatology) or a history of PPD or non-puerperal depression (Austin et al. 2010) as determined by the SCID-IV. Since anxiety and depression symptoms during pregnancy are associated with postpartum depressive symptomatology (Milgrom et al. 2008; O'Hara and Swain 1996) , women who met criteria for an anxiety disorder or depressive disorder not otherwise specified were included in the AR-PPD group; however, subjects who met SCID-IV criteria for a current MDE were excluded since the study was designed to identify a potential unifying biomarker in those women at risk for developing a major depressive episode.
Subjects were excluded for multiple gestation pregnancy, surrogate pregnancy, current major depressive episode (MDE), or lifetime history of manic episode or any psychotic disorder as determined by the Structured Clinical Interview for DSM-IV TR Disorders (SCID-IV), Patient Edition (First et al. 2001) ; elevated suicidal risk; and alcohol, tobacco or substance abuse/dependence in the 6 months prior to study entry. Based on medical and laboratory record review, subjects were excluded if they had active or a history of serious medical, neurological or endocrine disorder (e.g., adrenal, pituitary, thyroid, glucose or calcium homeostasis, polycystic ovarian syndrome). Prenatal vitamins and as-needed docusate was allowed during the study; other medication use was excluded. The Institutional Review Board (IRB) granted a waiver to review the medical records of obstetrics patients at our affiliated tertiary medical center during the study period between January 2010 and March 2013 and approved the study protocol. All subjects provided written informed consent, and each received monetary compensation.
Study procedures
We conducted a cross-sectional study. The study visit was conducted between 28 and 33 weeks gestation and included the TSST (Kirschbaum et al. 1993a) , serial saliva collection, and measurement of depression and anxiety. EPDS was administered on the day of the TSST to confirm continued eligibility. The TSST has been used in stress research to induce a moderate psychological stress in children (Buske- , adults and in pregnant women (Nierop et al. 2006b ) and is protocol-based (Kirschbaum et al. 1993a ). The TSST consists of an unprepared speech and mental arithmetic task performed in front of research team members (Kirschbaum et al. 1993a ) and elicits robust salivary cortisol responses (Meinlschmidt et al. 2010) . Subjects were instructed to avoid food intake for 2 hours and to abstain from caffeine, alcohol, and running or other strenuous activities during the 24 h prior the TSST. The TSST was performed between 1100 and 1700 h. Subjects rested seated during a 10-min acclimation phase. Using prepared scripts, subjects were then told that they would complete two tasks in the experiment. First, they were to assume the role of a job applicant who was invited for a personal interview with the company's job selection committee. Subjects were told to introduce themselves to the selection committee and convince them that they were the perfect applicant for their Bideal^job and to speak for the entire 5 min. Subjects were informed that the selection committee was trained in assessing nonverbal behavior and may ask additional questions during the interview. Subjects were informed that during the second task they would perform a serial subtraction test for five minutes. After subjects were informed of the two tasks, they were confronted with the public speaking and mental arithmetic tasks performed in front of a panel of three standing evaluators in white lab coats and carrying conspicuous handheld voice recorders. Evaluators were unknown to the subject, took notes on clip boards, and critiqued the subjects' performance during the stress tasks using prepared scripts. A debriefing occurred after final research assessments were completed.
Outcome measures
Research assessments included the following: SCID-IV, past medical and obstetric history, demographics, Edinburgh Postnatal Depression Scale (EPDS) (Cox et al. 1987) , and Childhood Trauma Questionnaire (CTQ) (Bernstein and Fink 1997) . As a history of childhood maltreatment can dampen the cortisol response to the TSST, the CTQ was administered to control for possible confounding effects (Carpenter et al. 2011 ) and was administered after subjects completed the TSST. The Spielberger State-Trait Anxiety Inventory (STAI-S) (state anxiety) was completed at time 0 (T0 = prior to TSST), T15 (immediately post-TSST), T25, T35, T45, and T75 min. Saliva samples were collected at the same time points as the STAI-S. As in other studies (Buss et al. 2009; Hellgren et al. 2013 ), we measured salivary cortisol to noninvasively and repeatedly examine bioavailable cortisol (Hampson et al. 2013) , as there are known peripartum changes in serum cortisol-binding protein which effect serum cortisol concentration.
Salivary cortisol quantification
Saliva was collected by Salivette® using a synthetic swab specifically designed for cortisol determination. Salivettes were centrifuged for 2 min at 1000×g, yielding a clear saliva sample. Cortisol concentration was analyzed by ARUP ® Laboratories (Salt Lake City, Utah) within 1 day of collection. Salivary-free cortisol concentration was analyzed using enzyme-linked immunosorbent assay (ELISA) with an analytical measurement range 0.31-77.91 nmol/L and lower limit of sensitivity of 0.19 nmol/L. Intra-assay coefficient of variation (CV) was 3-5 % and inter-assay CV was 3-9 % for mean cortisol concentrations of 4.41-11.59 nmol/L and 4.97-11.86 nmol/L, respectively.
Statistical analysis
Baseline characteristics were compared between our two primary comparison groups (AR-PPD vs. healthy comparison) using Fisher's exact test for categorical variables and Student's independent samples t test for continuous variables (with Satterthwaite adjustment for unequal variances, when appropriate). Pearson correlation coefficients were computed for comparisons between continuous variables of interest.
We analyzed cortisol changes during the visit longitudinally using generalized estimating equation (GEE) methods to control for the correlation within the subjects at the six time points during the TSST. Models were run examining potential associations between cortisol and AR-PPD/healthy comparison group categories, EPDS score, STAI-S score, and CTQ score. Main effects for risk group and variables of interest were modeled separately and then in combined models with risk group and one additional variable at a time, to examine any potential differences in scales or moods by risk group. We also examined STAI-S total score as the dependent variable to examine possible effects o f r i s k g r o u p o n S TA I -S s c o r e . We us e d a n autoregressive covariance structure in all of our GEE models. For main effects models, p values are reported from a z test that a single regression coefficient was equal to 0; for multivariable models, p values are reported from the overall type 3 test of any difference among levels of a factor (such as risk group) adjusting for other variables in the model.
In addition, we calculated area under the curve with respect to increase (AUC i ) using a trapezoidal formula for salivary cortisol at all six time points. Following the methods of Fisher et al. (2012) (Fisher et al. 2012 ) and based on recommendations from Pruessner et al. 2003 , (Pruessner et al. 2003 ), we retained negative AUC i values to avoid omitting information and examined the difference between positive and negative AUC i classifications. We dichotomized patients into those with positive AUC values, corresponding to a stronger increase than decrease in cortisol levels over time, and those with negative AUC values, corresponding to a stronger decrease than increase in cortisol values over time (Fisher et al. 2012) . AUC i at each time point was compared between the negative and positive classifications using Student's independent samples t test for continuous variables. We also examined if there was a difference between AUC i classifications between AR-PPD and healthy comparison women using a χ 2 test. All analyses were conducted in SAS Version 9.3 (SAS Institute, Inc., Cary, North Carolina). Study data was managed using Research Electronic Data Capture (REDCap) (O'Keane et al. 2011) .
Results
Study population characteristics at time of TSST
A total of 44 women participated in the study. The average age of subjects was 32.9 years (± standard deviation [SD] 4.8).
The majority of the subjects were white, non-Hispanic, employed, and married. There were no between group differences in number of children in household or household income (Table 1) . Overall, women were 31.3 weeks gestational age (±2.3 weeks) at the time of the TSST. AR-PPD women had a higher EPDS total score compared to HCS women. A majority (70.8 %) of the AR-PPD women had a past depression diagnosis, including 16.7 % with a past major depressive episode with postpartum onset, and 25 % had a past anxiety diagnosis.
Psychological rating scales and salivary cortisol response to Trier Social Stress Test
Mean STAI total score significantly differed between groups during the TSST (T0-T75, z = 2.71, df = 1, p = 0.007) with AR-PPD subjects reporting higher anxiety compared to HCS (Table 2) . However, a test of group-by-time interaction did not show a significant difference in the rate change in STAI-S by risk group over time (p = 0.23). AR-PPD subjects had a higher average CTQ score (13.41 ± 12.75) compared to HCS (3.95 ± 5.59). A comparison of these mean values using Student's t test showed a significant difference between groups (p = 0.003).
Overall, women had a cortisol level of 6.60 nmol/L (±2.32) at baseline (T0). There was no correlation between EPDS score and baseline cortisol (r = 0.1407, p = NS). The average cortisol values at each of the six TSST time points did not differ between AR-PPD and healthy comparison groups (Table 2) . Average cortisol values decreased in both groups over time (test for trend p = <.001), but did not differ by group (p = NS), suggesting that cortisol recovery was not prolonged in the AR-PPD group as compared to the HCS group, as hypothesized. GEE models examining longitudinal changes in cortisol to control for the inherent correlation between subjects did not differ significantly by risk group (z = −0.16, df = 1, p = NS), EPDS score (z = 0.65, df = 1, p = NS) or CTQ score (z = 0.58, df = 1, p = NS). STAI total score also did not affect cortisol concentration over time (z = 1.24, df = 1, p = NS) and did not differ by group (χ 2 = 0.05, df = 1, p = NS). Figure 1 depicts the change in mean cortisol (nmol/L) over time by AUC i group. There was a statistically significant difference in mean cortisol between the positive and negative AUC i groups at T25, T35, T45, and T75 (p = 0.006, 0.012, 0.012, 0.048, respectively). The majority (75 %) of subjects had a negative AUC i . No significant differences between the proportion of positive and negative AUC i classifications existed between AR-PPD and healthy comparison women (Fig. 2) . CTQ score did not differ by AUC i group, with a mean score of 7.18 (±8.95) in the positive AUC i subjects and a mean score of 9.94 (±11.90) in the negative AUC i subjects (t test p value = 0.49).
Discussion
This study, which examined salivary cortisol response to the TSST in late gestation in healthy women and those at-risk for PPD, yielded two main findings. First, in this study, healthy pregnant women and those at-risk of PPD had no detectable difference in salivary cortisol response to psychosocial stress induced by the TSST despite clinically significant betweengroup differences in current/past depression diagnoses and current symptomatology. 75 % of women in late gestation showed little elevation in salivary cortisol concentration during the TSST despite increases in state anxiety as measured by the STAI. Our finding is similar to what is reported with the cortisol awakening response across gestation (Entringer et al. 2010) and is comparable to findings by De Weerth et al. (2007) who reported that approximately half of the healthy pregnant women lacked a cortisol response to the TSST (i.e., <2.5 nmol/L change over time) (De Weerth et al. 2007) .
Our results are in contrast to a prior study which reported cortisol reactivity in early second trimester (i.e., 13-18 weeks) and early third trimester (i.e., 26-31 weeks) healthy euthymic women (Nierop et al. 2006a) . For a similar sample size (n = 30) among comparison groups, the absolute increase in cortisol reported in that study was greater than we report in our study. Potential explanations for the difference in findings may include the following: differences in the controlled time frames for collection of cortisol samples including a shorter baseline period compared to other studies and measurement of baseline cortisol at one time point before TSST rather than averaging across the resting period and study of all pregnant women (i.e., healthy and at-risk) at a later gestational age compared to other studies.
Childhood abuse is associated with increased HPA-axis sensitivity to stress in non-pregnant women with current symptoms of depression and anxiety (Heim et al. 2000) and in healthy non-pregnant subjects it is associated with hyporesponsiveness of the HPA-axis to psychosocial stress (Carpenter et al. 2007 (Carpenter et al. , 2011 . Although at-risk pregnant subjects reported greater childhood abuse than healthy subjects, there was no association between CTQ score and salivary cortisol measurements in late gestation. It is likely that we did not find an association between CTQ and cortisol SD standard deviation, AR-PPD at-risk postpartum depression, HCS healthy comparison subject, EPDS Edinburgh Postnatal Depression Scale, AUC i area under the curve with respect to the increase, where positive AUC values correspond to a stronger increase than decrease in cortisol levels over time and negative AUC values correspond to a stronger decrease than increase in cortisol values over time responsivity since there was only one AR-PPD subject whose CTQ physical abuse subscale score reached the moderate to severe threshold, a threshold which has been shown to be associated with cortisol hypo-responsivity (Carpenter et al. 2011) . Future studies should examine the role of maternal early life stress exposure as a risk for PPD. We hypothesized that women at-risk for PPD would demonstrate an exaggerated salivary cortisol response to the TSST based on findings of higher cortisol awakening response in patients with current and/or a past history of depression (Vreeburg et al. 2009 ) compared to those without depression. However, consistent with the results of several other studies (Harville et al. 2009; Hellgren et al. 2013; Meinlschmidt et al. 2010; Rothenberger et al. 2011; Shea et al. 2007; Voegtline et al. 2013 ), we did not find an association between cortisol concentration and anxiety rating scores induced by the psychosocial stressor, the findings suggest that the psychological and the endocrine response to acute psychosocial stress may represent two separate aspects of the stress response in late gestation when both the HPA (Buss et al. 2009; Entringer et al. 2010) and psychological responses to stress are attenuated (Glynn et al. 2001 ).
Strengths of this study include stringent inclusion/ exclusion criteria; subjects underwent thorough research diagnostic and symptomatic evaluations, including the CTQ. Although childhood abuse has profound effects on the HPA-axis, measurement of its moderating effect on cortisol reactivity is not widespread among studies, making comparisons between studies challenging. Another strength of this study is that salivary cortisol was determined by enzyme immunoassay which is preferable to serum total cortisol in the assessment of dynamic HPA activity (Gozansky et al. 2005 ) and reflects unbound concentrations of cortisol in serum. To maximize salivary cortisol recovery, we used a polyester tampon rather than a cotton tampon within the Salivette® (Hansen et al. 2008) . To reduce the variance of salivary cortisol between subjects, the majority (80 %) of subjects completed the TSST between 1200 and 1700. We chose this time frame to maximize our ability to elicit a cortisol response by controlling for the difference in circadian variation to the TSST which has been reported in pregnancy, with smaller or absent cortisol reactivity earlier in the day (De Weerth et al. ); however, 20 % women completed the TSST between 1100 and 1200 due to the challenges in scheduling. No salivary stimulants were utilized. Also, medication use in our study was restricted to prenatal vitamins and stool softeners, and all subjects were nonsmokers and not using alcohol, so we were able to limit the impact of these on cortisol concentrations. The sample size among comparison groups, while not large, is comparable to published reports (Hellgren et al. 2013; Meinlschmidt et al. 2010 ). The differences we observed were not as great as those we used to plan the study; however, a post-experiment power analysis would not be informative in this situation (Hoenig and Heisey 2001; Simon 1986 ). Limitations of this study include our sample size and investigation of psychological and endocrine responses but not autonomic responses to the TSST. Additionally, another limitation is that we could not include a healthy non-pregnant comparative population due to limits of the funding mechanism which supported this study. Inclusion of this comparison group would clarify if our results were due to a gestationdependent diminution of the stress response or if the TSST did not achieve an adequate stress response in all subjects, an alternative explanation for our results. We designed the study with an approach consistent with the Research Domain Criteria (RDoC) (Ostergaard et al. 2014 ) and included a heterogeneous at-risk population. However, since the AR-PPD group included a variety of clinical phenotypes, the underlying neuroendocrine mechanisms for each clinical phenotype may differ (Schiller et al. 2014 ) and inclusion as a group may have obscured the ability to see between-group differences in cortisol reactivity. Antepartum anxiety is a risk factor for PPD; in our study, 62 % of AR-PPD subjects had an anxiety disorder. There is an emerging literature describing the effects of anxiety on cortisol during pregnancy (Kane et al. 2014; King et al. 2010; O'Connor et al. 2014) and in the postpartum (Labad et al. 2011; Lord et al. 2011 ) but substantial methodological variation among studies makes it difficult to identify clear associations. The study sample size did not allow us to examine potential differences in cortisol reactivity among the clinical phenotypes.
The majority of previous studies examining the relationship between HPA functioning and peripartum mood and anxiety have focused on the postpartum period. HPA axis reactivity to stress is reduced during the postpartum period (Brunton et al. 2008; Tu et al. 2005) , and suppression of HPA reactivity in the postpartum is associated with PPD (Cox et al. 2015; Magiakou et al. 1996; Taylor et al. 2009 ). Preliminary data suggest antepartum HPA axis abnormalities may contribute to the development of PPD (Bloch et al. 2005; Nierop et al. 2006b ). Preclinical and clinical studies indicate that hormonal adaptations during late pregnancy affect endocrine mechanisms associated with maternal postpartum physiological functioning (Brunton et al. 2008; Meinlschmidt et al. 2010 ) but few studies have investigated the relationship between antepartum HPA functioning with maternal peripartum mood. Furthermore, more studies are needed to examine antepartum HPA functioning in relationship to infant neurodevelopmental outcomes, especially in antepartum women AR-PPD and antepartum depressed women. Understanding how stress impacts maternal HPA functioning during pregnancy is critical to understanding potential neuroendocrine mechanisms of risk for perinatal depressive and anxiety disorders and the impact on the developing fetus (Bolten et al. 2013 ). This study builds upon prior research on HPA reactivity in the peripartum period (Entringer et al. 2010; Hellgren et al. 2013; Meinlschmidt et al. 2010) and includes a novel and understudied population, women at-risk for developing PPD. Acknowledgments This study was supported by the National Center for Advancing Translational Sciences, National Institutes of Health Grant (UL1 TR000161), and National Institutes of Health Grant (5K23MH097794) awarded to Dr. Deligiannidis. The sponsoring agency had no further role in the study design and analysis, the writing of the report, or the decision to submit the paper for publication. The authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily reflect the position of the NIH.
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